A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.

USA: A recent study published in JAMA Network Open has found that the use of glucagon-like peptide-1 (GLP-1) receptor ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-r ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Clinical practice guidelines provide recommendations for pregnancy care in individuals with preexisting diabetes mellitus.